Chronic THC impaired working memory in monkeys but did not change dopamine D2/D3 receptor levels

A study of six rhesus monkeys receiving daily THC for 12 weeks found persistent working memory impairment that recovered within two weeks of abstinence, with no changes in dopamine D2/D3 receptor availability.

John, William S et al.·The Journal of pharmacology and experimental therapeutics·2018·Moderate EvidenceAnimal StudyAnimal Study
RTHC-01706Animal StudyModerate Evidence2018RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Six adult male rhesus monkeys were tested on cognitive tasks using touchscreen tests (CANTAB) before and during 12 weeks of daily THC (1.0-2.0 mg/kg).

Acute THC impaired cognitive performance in a task-specific manner and reduced food-motivated responding and body temperature.

During chronic treatment, THC produced persistent residual impairment only to working memory, measured 22 hours after each dose. Other cognitive domains showed tolerance development.

Working memory recovered to baseline within two weeks of abstinence.

PET imaging comparing four THC-treated monkeys to four drug-naive controls found no difference in dopamine D2/D3 receptor availability, suggesting the cognitive effects were not driven by changes in dopamine receptor density.

The authors suggested that interventions targeting working memory could improve treatment outcomes for cannabis use disorder.

Key Numbers

6 monkeys, 12 weeks of daily THC (1.0-2.0 mg/kg s.c.). Working memory was the only domain with persistent residual impairment at 22 hours post-dose. Recovery occurred within 2 weeks of abstinence. No significant difference in D2/D3 receptor availability between 4 THC-treated and 4 control monkeys.

How They Did This

Primate study with six rhesus monkeys. Acute THC dose-response testing followed by 12 weeks of daily chronic THC. Cognitive assessment via CANTAB touchscreen battery. Dopamine D2/D3 receptor availability measured by PET with [11C]-raclopride in a subgroup (4 THC-treated vs 4 controls).

Why This Research Matters

This primate study provides a controlled look at how chronic THC affects cognition over time, something impossible to study as rigorously in humans. The finding that working memory was selectively vulnerable while other functions showed tolerance is clinically relevant for understanding cannabis use disorder.

The Bigger Picture

The selective vulnerability of working memory to chronic THC, combined with its recovery after abstinence, suggests that cannabis-related cognitive impairment may be reversible. The lack of D2/D3 receptor changes challenges the theory that cannabis impairs cognition through dopaminergic mechanisms.

What This Study Doesn't Tell Us

Very small sample size (6 monkeys, 4 per group for PET). Only male monkeys studied. THC doses may not map directly to human consumption patterns. D2/D3 receptors are one component of the dopamine system; other aspects (release, synthesis, D1 receptors) were not measured.

Questions This Raises

  • ?What neurochemical mechanism drives the selective working memory impairment if not D2/D3 receptors?
  • ?Would longer THC exposure lead to slower recovery?
  • ?Do these findings differ in female primates?

Trust & Context

Key Stat:
Working memory impairment persisted during chronic THC but recovered within 2 weeks of abstinence
Evidence Grade:
Moderate. Primate model with controlled conditions and validated cognitive measures, but very small sample limits statistical confidence.
Study Age:
Published in 2018. Subsequent research has continued exploring the relationship between chronic cannabis use, cognition, and dopamine signaling.
Original Title:
Chronic Δ9-THC in Rhesus Monkeys: Effects on Cognitive Performance and Dopamine D2/D3 Receptor Availability.
Published In:
The Journal of pharmacology and experimental therapeutics, 364(2), 300-310 (2018)
Database ID:
RTHC-01706

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Why is this study done in monkeys instead of humans?

Rhesus monkeys share close brain anatomy with humans and can be studied under tightly controlled conditions (exact THC dose, no other drug use, pre-drug cognitive baseline). This level of control is impossible in human studies of chronic cannabis use.

Does this mean cannabis does not affect dopamine?

It means chronic THC did not change the density of D2/D3 dopamine receptors in these monkeys. Cannabis can still affect dopamine signaling through other mechanisms like dopamine release or other receptor types that were not measured here.

Read More on RethinkTHC

Cite This Study

RTHC-01706·https://rethinkthc.com/research/RTHC-01706

APA

John, William S; Martin, Thomas J; Solingapuram Sai, Kiran Kumar; Nader, Susan H; Gage, H Donald; Mintz, Akiva; Nader, Michael A. (2018). Chronic Δ9-THC in Rhesus Monkeys: Effects on Cognitive Performance and Dopamine D2/D3 Receptor Availability.. The Journal of pharmacology and experimental therapeutics, 364(2), 300-310. https://doi.org/10.1124/jpet.117.244194

MLA

John, William S, et al. "Chronic Δ9-THC in Rhesus Monkeys: Effects on Cognitive Performance and Dopamine D2/D3 Receptor Availability.." The Journal of pharmacology and experimental therapeutics, 2018. https://doi.org/10.1124/jpet.117.244194

RethinkTHC

RethinkTHC Research Database. "Chronic Δ9-THC in Rhesus Monkeys: Effects on Cognitive Perfo..." RTHC-01706. Retrieved from https://rethinkthc.com/research/john-2018-chronic-9thc-in-rhesus

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.